Videos

Dr Brian Ference sets the record straight on questions about benefit in FOURIER

In discussions at ACC.2017, some have suggested that the results of FOURIER were less than anticipated from the meta-analysis of statin trials by the Cholesterol Treatment Trialists’ Collaboration (CTTC) (1). PCSK9 Forum Editor Dr Brian Ference (Division of Cardiovascular Medicine, Wayne State University School of…

Events are the driver in PCSK9 cardiovascular outcomes trials

A recurrent question at ACC.2017 was why FOURIER had a short duration of follow-up, given the average duration of the statin trials was typically in the region of 4-5 years. This debate has been fanned by colourful but misinformed reports in the investment media (1).’…

Prof Evan Stein: What are the key messages from FOURIER?

Prof Ulf Landmesser: How can we ensure the best value from PCSK9 inhibitor therapy?

Prof Steve Nicholls: How can FOURIER improve our clinical practice?

Prof Ulf Landmesser: How will FOURIER impact practice?

Prof Steve Nicholls: Is there a link between the benefit of evolocumab observed in GLAGOV & FOURIER?

Prof Steve Nicholls: Is FOURIER a game changer?

Prof Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C

In a new report today, Professor Robert Rosenson (Mount Sinai Icahn School of Medicine, Mount Sinai Hospita, New York, USA) discusses results from the REGARDS study. This study investigated whether there was any link between PCSK9 genetic variants associated with low LDL cholesterol and cognitive…

VIDEO: Prof Raul Santos: How can PCSK9 monoclonal antibody therapy be cost effective?

Prof Francois Mach: How will FOURIER impact guidelines

Prof Francois Mach discusses EBBINGHAUS

Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition

Prof Henry Ginsberg: Data needed on the diabetes subgroup in FOURIER

Prof Raul Santos: SPIRE trials with bococizumab

The data from the SPIRE programme, especially SPIRE-1 and SPIRE-2 the cardiovascular outcomes studies was also illuminating. PCSK9 Forum Editor Professor Raul Santos, one of the authors, gives his view.

Prof Philip Barter: How do we translate the FOURIER data to clinical practice?

Prof John Chapman: FOURIER – Why was there no significant effect on CV mortality?

Prof John Chapman: FOURIER endpoint data

PCSK9 Forum Editor Professor Philip Barter discusses FOURIER

Take home message on FOURIER